List is tentative, and subject to change at any time.
Universities
University of Colorado Anschutz Medical Campus
Technologies coming soon!
Universities
Kansas State University
Technologies coming soon!
Universities
Mayo Clinic
Technologies coming soon!
Universities
Ohio State University
Mps1/TTK kinase inhibitor to treat hematological malignancies
The TTK kinase is critical for proper function of the spindle assembly checkpoint, and its upregulation is associated with poor clinical outcomes in a variety of cancer types.
Selective estrogen receptor modulator (ER-Beta Agonist) targets cancer
The estrogen receptors, alpha and beta, are both responsive to endogenous estrogen, but modulate different biological processes.
DHODH inhibitors to treat hematological malignancies
Dihydroorotate dehydrogenase (DHODH) is a key enzyme in the de novo pyrimidine synthesis pathway.
Universities
Purdue University
Antimicrobial Peptides Targeting Intracellular Bacteria
Researchers at Purdue University developed antimicrobial agents against intracellular human pathogens with improved efficacy compared to the group’s previous-generation compounds.
Therapeutic targets metastatic prostate cancer
Researchers at Purdue University have developed a targeted therapeutic option for treating metastatic prostate cancer, the second leading cause of cancer death for men in the United States.
Treat glioblastoma with multi-functional natural killer cells and small molecule autophagy inhibitor
Researchers at Purdue University have developed an immunotherapy approach combining cell therapy and a small molecule inhibitor to treat glioblastoma.
Universities
University of Colorado-Boulder
Prevent, alleviate side effects of radiation or radiotherapy
Using C. elegans as an animal model to study radiation-induced bystander effects (RIBE), researchers at the University of Colorado Boulder have identified a highly conserved cysteine protease, cathepsin B, as the first RIBE factor.
Novel selective HDAC6 inhibitors show promise for cancer and beyond
The researchers of the University of Colorado developed a series of hydroxamic acid derivatives as HDAC6 selective inhibitors.
Universities
University of Iowa
Nanoparticle vaccine fights respiratory syncytial virus
Inventors at the University of Iowa have developed a respiratory syncytial virus vaccine. It is a nanovaccine consisting of viral proteins encapsulated by biodegradable polyanhydride polymers.
Pristimerin-loaded nanoparticles enhance anti-neoplastic activity of platinum compounds
Endometrial cancer is the most frequent gynecological cancer and is often treated using platinum-based therapies such as cisplatin.
Non-viral formulation delivers lubricin genes
Post-traumatic osteoarthritis weakens the regulation of lubricin gene and increases shear stress within the joints.
Universities
University of Kansas
Technologies coming soon!
Universities
University of Kentucky
Technologies coming soon!
Universities
University of Minnesota
Humanized antibodies to treat diabetes, range of tissue injuries
SerpinB13 is a protease inhibitor linked to autoimmune inflammation and Type 1 diabetes (T1D).
Agmatine-based pain treatment avoids opioid addiction
The search for better analgesics has focused on non-addictive alternatives. Agmatine, the decarboxylated product of arginine, is a potential candidate for novel therapeutics.
Universities
University of Missouri
Dual-biomarker targeting agent helps diagnose, treat prostate cancer
A dual diagnostic and therapeutic compound binds GRPr and PSMA with high specificity and sensitivity.
Gene therapy improved with new AAV hybrid vector system
Novel dual- and tri-AAV hybrid vector systems increase the upper size limit of gene constructs from <5kb to <15kb.
Novel antibiotics target beta-lactamase
Researchers at the University of Missouri have developed novel inhibitors of beta-lactamase, a bacterial enzyme that provides resistance to β-lactam antibiotics.
Universities
University of Nebraska Medical Center
Technologies coming soon!
Universities
University of Oklahoma
Antitoxin peptides inhibit clostridium difficile
Researchers at the University of Oklahoma have discovered a class of antitoxin peptides that inhibit a critical clostridium difficile virulence factor.
Persephacin excels as broad-spectrum antifungal
Persephacin, a novel fungal isolate, strongly inhibits a broad range of pathogenic fungi while exhibiting low cytotoxicity to mammalian cells.
Peptides inhibit Alzheimer’s disease
Bioactive synthetic peptides derived from neutrophil proteins, cathepsin G and CAP37, can inhibit and reverse the formation of toxic amyloid beta aggregates.
Universities
University of Wisconsin
Nanoparticles deliver bioactive molecules
A new hybrid nanocapsule uses a silica, metal and organic framework designed to deliver protein, nucleic acid or hydrophilic drugs.
Paclitaxel prodrug enhances anticancer efficacy
A new formulation of paclitaxel fuses the drug to an oligo-lactic acid (oLA) encapsulated in a PEG-PLA micelle.
New treatment for Status Epilepticus ‘starves’ problematic neurons
This technology uses 2-deoxy-D-glucose (2DG) as a novel treatment for Status Epilepticus (SE).